Monoclonal Purified F VIII for Continuous Infusion: Stability, Microbiological Safety and Clinical Experience

Summary

Replacement therapy for patients with hemophilia A postoperatively or for major hemorrhage, administered as a continuous infusion, is efficient and reduces the requirement for factor VIII (F VIII). The convenience of the method is increased by using a minipump and not diluting the concentrate further after reconstitution. A monoclonally purified F VIII concentrate (Monoclate-P®), was evaluated for its stability after reconstitution in different infusion systems, for its microbiological safety as well as clinical safety and efficacy in continuous infusion. The F VIII activity was unaffected by 2 of the 3 infusion systems at room temperature during 15 days, whereas in the third (CADD®-1) it decreased below 80% of initial value after 3-7 days. Addition of heparin (1 U/ml) or low molecular weight heparin (1 anti-Xa U/ml), which are used to prevent thrombophlebitis at the site of infusion, did not affect the stability. Nine out of 9 samples taken from the infusion systems after 3 days and again after 7 days were sterile. After inoculation with Staphylococcus aureus or Escherichia coli the bacterial growth in samples of the reconstitued concentrate was not different from that in lidocain in saline or heparin in saline. F VIII was given in continuous infusion with a minipump (Infu-Med™) to 12 patients undergoing major surgery and 8 patients with major hemorrhage for a total of 157 days. A progressive decrease of the clearance was seen during the first 5 days of infusion from 3.0 to 1.7 ml/kg/h. Hemostasis was effectively achieved, and no infectious complications were registered. The administration of monoclonally purified F VIII with a minipump is safe, efficient and convenient and reduces the consumption of F VIII when high doses are needed. Some patients can be discharged earlier and admission to the hospital may even be unnecessary, since high and steady F VIII levels can be maintained.

• References

• 1 McMillan CW, Webster WP, Roberts HR, Blythe WB. Continuous intravenous infusion of factor VIII in classic haemophilia. Br J Haematol 1970; 18: 659-667
• 2 Blatt PM, White GCII, McMillan CW, Roberts HR. Treatment of anti-factor VIII antibodies. Thromb Haemost 1977; 38: 514
• 3 Levin J, Ness PM, Bell WR. Continuous infusion of factor VIII concentrate for therapy of hemophilia A. Blood 1981; 58: 220a
• 4 Hathaway WE, Christian MJ, Clarke SL, Hasiba U. Comparison of continuous and intermittent factor VIII concentrate therapy in hemophilia A. Am J Hematol 1984; 17: 85-8
• 5 Bona RD, Weinstein A, Weisman SJ, Bartolomeo A, Rickies fr. The use of continuous infusion of factor concentrates in the treatment of hemophilia. Am J Hematol 1989; 32: 8-13
• 6 Weinstein RE, Bona RD, Rickies FR. Continuous infusion of monoclonal antibody-purified factor VIII. Am J Hematol 1991; 36: 211-212
• 7 Martinowitz U, Schulman S, Gitel S, Horoszowski H, Heim M, Varon D. Adjusted dose continuous infusion of factor VIII in patients with haemophilia A. Br J Haematol 1992; 82: 729-34
• 8 Schulman S, Gitel S, Martinowitz U. The stability of factor VIII concentrates after reconstitution. Am J Hematol 1994; 45: 217-23
• 9 Morfini M, Lee M, Messori M. The design and analysis of half-life and recovery studies for factor VIII and factor IX. Thromb Haemost 1991; 66: 384-6
• 10 Matucci M, Messori A, Donati-Cosi G, Longo G, Vannini S, Morfini M, Tendi E, Rossi-Ferrini P. Kinetic evaluation of four factor VIII concentrates by model independent methods. Scandinavian Journal of Haematology 1985; 34: 22-28
• 11 Longo G, Matucci M, Messori A, Morfini M, Rossi-Ferrini P. Pharmacokinetics of a new heat-treated concentrate of factor VIII estimated by model-independent methods. Thrombosis Research 1986; 42: 471-476
• 12 Martinowitz U, Varon D, Yonash P, Bar-Maor A, Brenner B, Leibovitch I, Heim M. Circumcision in hemophilia: the use of fibrin glue for local hemostasis. Journal of Urology 1992; 148: 855-7
• 13 Hermens WTH. Dose calculation of human factor VIII and factor IX concentrates for infusion therapy. Handbook of Hemophilia, Part II Brinkhouse KM, Hemker HC. America Elsevier Publishing Co; New York: 1975: 569